iSchemaView (doing business as RapidAI)

Golden, CO All United States companies → — Founded 2011

Imaging AI Specialist

Emergency Medicine Neurology Neurosurgery Radiology

Neurology AI Radiology & Imaging AI Triage & ER/ICU AI

Series C — $103M

Claim this company

Products

Rapid Neuro3D

iSchemaView (doing business as RapidAI)

Neurology AI

Rapid Neuro3D by iSchemaView (RapidAI) is an AI-powered neuroimaging platform that provides automated analysis of CT and MRI scans to assist physicians in rapid diagnosis and treatment decisions for stroke patients.

Contact vendor for pricing details.

Rapid Aneurysm Triage and Notification

iSchemaView (doing business as RapidAI)

Neurology AI

Rapid Aneurysm Triage and Notification by iSchemaView (RapidAI) is an FDA-cleared AI software that analyzes CT angiography images to detect and prioritize suspected saccular aneurysms, enhancing workflow and supporting longitudinal monitoring for improved patient care.

Contact vendor for pricing.

See all 2 products →

About iSchemaView (doing business as RapidAI)

RapidAI, doing business as iSchemaView, is a leading healthcare AI company that provides a comprehensive clinical AI platform designed to enhance assessment and transform care across various service lines. For physicians, the Rapid Enterprise™ Platform offers deep clinical decision-making support, particularly in neurovascular, cardiac, and vascular conditions. It leverages artificial intelligence to analyze medical images, such as CT and MRI scans, providing high-quality, automated results and critical insights within minutes. This capability aids in faster, more accurate diagnostic and treatment decisions for conditions like stroke, cerebral aneurysms, and pulmonary embolisms, even extending the treatment window for acute stroke patients based on landmark clinical trials.

The platform goes beyond basic triage and notification by offering interpretive, diagnostic, and predictive information with unparalleled specificity and sensitivity. It integrates seamlessly into hospital workflows via PACS systems and a mobile app, enabling real-time collaboration among care teams, remote access to patient cases, and streamlined communication. RapidAI’s solutions are clinically validated, with numerous FDA clearances, and are utilized in over 2,500 hospitals across more than 100 countries, demonstrating a significant impact on improving patient outcomes and operational efficiencies in emergency neurovascular care and beyond.

Focus Areas

Neurovascular Cardiac & Vascular Radiology Stroke Aneurysm Aortic Disease Trauma Oncology Orthopedic Deep Clinical AI Enterprise Imaging Workflow Solutions

Business Intelligence

Key Investors	Vista Equity Partners, Cullom Capital, Lennertz & Co., Listwin Ventures, Vista Credit Partners
Partnerships	Amazon Web Services (AWS), Saudi Health Holdings Company (HHC)
Acquisitions	EndoVantage (June 2020)
Technology	Rapid Enterprise™ Platform, Rapid Edge Cloud (hybrid cloud and on-premise infrastructure), AI Orchestrator, Navigator Pro
FDA Clearances	Multiple. Specific clearances include: Rapid DeltaFuse™, Rapid LMVO, Rapid MLS, Rapid OH, Rapid Aortic for measurement (5 modules cleared November 2025); Rapid NCCT Stroke (cleared April 2023); Aortic Management (cleared November 2025). cleared products (estimated)

What Physicians Need to Know

Neurovascular

RapidAI offers comprehensive AI-driven solutions for neurovascular conditions, including hemorrhagic stroke (IPH, IVH, SDH, SAH), ischemic stroke (LVO, MeVO), and aneurysms. Their platform provides AI-driven bleed assessment, supports decisive stroke triage from detection to destination, and helps surface silent risks and track changes in aneurysms.

Cardiac & Vascular

Specializes in modernizing pulmonary embolism (PE) care and aortic disease management. RapidAI helps identify treatment-eligible PE patients, optimizes care team communication, and provides automated analysis of CT scans to identify aortic disease, generate measurements, and simplify surveillance by tracking changes over time.

Radiology

RapidAI's solutions boost diagnostic confidence and streamline radiology workflows. Navigator Pro provides imaging prioritization and AI decision support, surfacing key findings early, cutting down manual steps, and keeping prioritization, findings, communication, and reporting in one workspace. Lumina 3D offers automated CTA reconstructions of the head, neck, and aortic arch within minutes, improving throughput and reducing scan backlog.

Stroke

A core specialization, RapidAI provides AI-enabled software for viewing, processing, and analyzing CT images (NCCT, CTA, CTP) to assist in assessing patients with suspected stroke. Solutions like Rapid ICH, Rapid ASPECTS, Rapid CTA, and Rapid LVO support faster clinical decision-making, help identify patients for thrombectomy, and can reduce radiology-report turnaround times.

Aneurysm

Rapid Aneurysm is a clinically validated platform that enhances diagnostic confidence and consistency in detecting intracranial aneurysms. It combines 3D visualization, growth tracking, and automated measurement, providing a comprehensive view and aiding in assessing rupture risk with proper surveillance and quantification.

Aortic Disease

Rapid Aortic automatically analyzes C/A/P CT scans to aid in the identification of aortic disease, including non-contrast and post-treatment scans. It generates automated measurements (six zonal maximums, 18 landmark measurements) and simplifies surveillance by comparing current and prior scans to track changes over time.

Trauma

RapidAI offers solutions for trauma care, particularly for head trauma. Rapid SDH (Subdural Hematoma) and Rapid ICH (Intracerebral Hemorrhage) leverage AI to detect suspected hemorrhages, provide rapid notifications to the trauma team, and support timely transfer and treatment decisions.

Oncology

While not a primary explicit specialization listed with dedicated modules, RapidAI's Deep Clinical AI and Enterprise Imaging platform are designed to support various disease states across the care spectrum, and its capabilities for advanced visualization, quantification, and longitudinal tracking can be leveraged in oncology for monitoring and assessment.

Orthopedic

RapidAI has expanded its solutions to include orthopedics. Specific modules like Rapid VCF (Vertebral Compression Fractures) detect suspected fractures in routine CT scans, and Rapid C-Spine identifies suspected cervical spine fractures from NCCT imaging, aiming to improve outcomes and lower costs through early detection and prompt medical attention.

Deep Clinical AI

RapidAI's core differentiator, Deep Clinical AI, goes beyond simple anomaly detection and triage. It measures, localizes, visualizes, characterizes disease, and tracks changes over time. This intelligence provides contextual insights, reduces cognitive burden, and supports faster, clearer decision-making across various disease states.

Enterprise Imaging

The Rapid Enterpriseu2122 Platform is a unified solution for an intelligent imaging ecosystem. It consolidates clinical AI apps into a single system, integrating AI-augmented image capture, RIS/PACS connectivity, worklist prioritization, clinical decision support, and structured/automated reporting. It's designed for cross-disciplinary deployment of deep clinical AI.

Workflow Solutions

RapidAI provides truly integrated workflows that connect intelligence, workflow, and teams across the health system. This includes real-time collaboration and alerts via the Rapid mobile app, in-app messaging, and seamless integration with PACS, EHR, and worklists to streamline processes, accelerate care coordination, and improve operational efficiency.

Physician Tip

RapidAI empowers physicians by providing real-time, actionable insights that lead to faster, more confident clinical decisions and improved patient outcomes. The platform significantly reduces cognitive burden by automating measurements, visualizing anomalies, and pre-fetching relevant data, allowing physicians to focus on interpretation and clinical judgment. Its integrated workflow solutions facilitate seamless communication and coordination across multidisciplinary care teams, from the ER to the OR and beyond. Physicians benefit from a comprehensive view of patient data, including automated 3D renderings and longitudinal tracking, which supports both acute treatment and long-term patient management. The clinically validated nature of RapidAI's algorithms, backed by extensive research, instills trust and helps expand treatment windows and guidelines.

RapidAI's Enterprise Platform is designed for seamless integration across the healthcare ecosystem. It connects directly with existing IT infrastructure, including PACS, EHR, RIS, worklists, and reporting systems, ensuring a unified experience rather than adding another layer to manage. The platform also supports the integration of curated third-party AI algorithms, expanding its capabilities and providing a comprehensive suite of tools within a single workflow. The Rapid Edge Cloud, a hybrid infrastructure, ensures secure, reliable, and scalable deployment, meeting complex regional security, compliance, and data privacy requirements.

At a glance

Founded 2011

HQ Golden, CO · United States

Team size 267

CEO Karim Karti

Funding Series C — $103M

FDA clearances Multiple. Specific clearances include: Rapid DeltaFuse™, Rapid LMVO, Rapid MLS, Rapid OH, Rapid Aortic for measurement (5 modules cleared November 2025); Rapid NCCT Stroke (cleared April 2023); Aortic Management (cleared November 2025). (estimated)

Products 2

Products by iSchemaView (doing business as RapidAI)

2 products in the directory

Rapid Neuro3D

iSchemaView (doing business as RapidAI)

Neurology AI

Contact vendor for pricing details.

Rapid Aneurysm Triage and Notification

iSchemaView (doing business as RapidAI)

Neurology AI

Contact vendor for pricing.

What the Web Says

RapidAI (iSchemaView) generally receives positive reviews for its AI-powered stroke analysis software, which is praised for its speed, accuracy, and impact on patient outcomes. Employer reviews are mixed, with some highlighting a positive culture and others pointing to challenges with management and work-life balance.

Overall: Mixed

Strengths

RapidAI's stroke analysis software is highly effective, fast, and accurate, significantly improving treatment times and patient outcomes.
The software is user-friendly and integrates well into existing hospital workflows.
Many users appreciate the company's commitment to innovation in healthcare technology.
Some employees praise the company culture, intelligent colleagues, and the meaningful impact of their work.
The product is considered a valuable tool for neurologists and stroke teams.
Good benefits package for employees.

Limitations

Some employer reviews mention issues with management, communication, and lack of clear direction.
Work-life balance can be a challenge for some employees, with long hours reported.
Rapid growth has led to some organizational growing pains and changes.
Specific pricing details or cost-effectiveness are not always highlighted as a pro, suggesting it might be a consideration for some institutions.
Some users on Reddit express concerns about the proprietary nature of the software and potential vendor lock-in.
Limited negative product reviews, but some minor UI/UX suggestions have been noted.

Based on reviews from: G2, Glassdoor, Capterra, Reddit, Healthcare IT News (implied from general healthcare IT reviews)

Last updated: 2026-07-20

Videos

News, demos, and interviews about iSchemaView (doing business as RapidAI).

Loading videos...

Videos load interactively. If none appear, search YouTube for iSchemaView (doing business as RapidAI) →

View all on YouTube

Press & Coverage

RapidAI Press Releases

RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts

RapidAI announced 28 scientific abstracts accepted at the International Stroke Conference (ISC) 2026, showcasing new clinical research on AI-driven gains in aneurysm detection, stroke interpretation, and enterprise imaging efficiency.

2026-02

RapidAI Press Releases

RapidAI Extends the Reach of Deep Clinical AI with Five New FDA Clearances

RapidAI received U.S. FDA clearance for five new imaging modules: Rapid DeltaFuseu2122, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement, significantly expanding its Rapid Enterpriseu2122 Platform.

2025-11

RapidAI Press Releases

RapidAI Earns FDA Clearance for Rapid Aortic, Bringing AI-Driven Aortic Measurements and Surveillance to Care Teams

RapidAI announced U.S. FDA clearance of Aortic Management, part of the Rapid Aortic product, a comprehensive deep clinical AI solution for acute assessment and longitudinal management of aortic disease.

2025-11

RapidAI Press Releases

RapidAI and AWS Strengthen Relationship: Accelerate Global Deployment of Deep Clinical AI

RapidAI and Amazon Web Services (AWS) announced a strengthened working relationship to accelerate the global adoption and scalability of deep clinical AI in healthcare through co-development and go-to-market alignment.

2025-12

RapidAI Press Releases

RapidAI Announces $75 Million Growth Investment Led by Vista Credit Partners

RapidAI secured $75 million in Series C funding led by Vista Credit Partners, intended to fuel continued innovation of its advanced clinical decision and workflow support technology and expand its leadership in clinical AI solutions.

2023-07

American Heart Association Journals

RapidAI Compared With Human Readers of Acute Stroke Imaging for Detection of Intracranial Vessel Occlusion | Stroke: Vascular and Interventional Neurology

This article discusses a study comparing RapidAI with human readers for detecting intracranial vessel occlusion in acute stroke imaging, highlighting the use of LR graphs for simultaneous comparison of positive and negative likelihood ratios.

2024-01

Canadian Journal of Health Technologies

RapidAI for Stroke Detection and AI Implementation Review

This review provides an implementation assessment for RapidAI as an AI-enabled medical device for stroke detection, serving as a foundational report for AI management in Canada.

2024-11

RapidAI Blog

The market has changed: Frost & Sullivan's 2026 Radar shows who's leading it.

Frost & Sullivan's 2026 Radaru2122: Intelligent Imaging Analysis Systems report ranked RapidAI among the leaders, scoring 4.8 out of 5.0 on Innovation, emphasizing the performance of AI built for clinical depth.

2026-01

Frequently Asked Questions

What clinical areas and disease states does RapidAI's platform support, and what are its core product capabilities?

RapidAI's Enterprise Platform offers deep clinical AI solutions across neurovascular conditions like stroke, aneurysm, and trauma, as well as cardiac and vascular diseases such as pulmonary embolism and aortic disease. The platform provides advanced imaging analysis, automated measurements, 3D reconstructions, and longitudinal tracking to support faster, more informed clinical decision-making and improve patient outcomes.

How does RapidAI ensure compliance and regulatory approval for its AI-driven solutions?

RapidAI maintains robust regulatory compliance through numerous FDA clearances for its imaging modules, including recent expansions for neurology, vascular, and radiology applications. The company's commitment to clinically validated AI, backed by over 700 clinical studies, ensures its products meet high standards for safety and efficacy, with some modules also qualifying for CMS New Technology Add-on Payments.

What is RapidAI's pricing model, and what kind of ROI can healthcare organizations expect?

RapidAI utilizes an annual subscription model, with pricing customized based on factors like institution size, specific modules required, and deployment scale, rather than publicly listed rates. While exact ROI varies, the platform aims to deliver cost-benefit advantages through increased efficiency, reduced cognitive burden for radiologists, and improved patient outcomes, which can lead to significant time and cost savings.

What level of customer support and implementation assistance does RapidAI provide?

RapidAI offers 24/7/365 customer support globally via email and phone, with a dedicated team of technical services experts fluent in multiple languages. The company also boasts an efficient implementation workflow, typically enabling hospitals to go live with the RapidAI platform within two weeks, ensuring minimal disruption.

What strategic partnerships does RapidAI have, and how do they enhance its offerings?

RapidAI engages in strategic partnerships with technology leaders, including an expanded collaboration with Amazon Web Services (AWS) for co-developing advanced AI tools and foundational model infrastructure. They also partner with healthcare providers like Saudi Health Holdings Company for enterprise-wide AI deployment and organizations like Penumbra for specific disease states such as pulmonary embolism, extending their reach and capabilities.

What is the company's financial stability and market presence, given its role in critical care AI?

RapidAI, founded in 2011/2012, has demonstrated strong financial stability, having been profitable since its market entry and securing over $100 million in funding through Series C. It is a global leader, with its platform used in over 2,500 hospitals across more than 100 countries, underscoring its significant market presence and reliability in critical care AI.

How does RapidAI's 'Deep Clinical AI' approach differ from other AI solutions in enterprise imaging and workflow?

RapidAI's 'Deep Clinical AI' goes beyond simple triage and detection, focusing on algorithms that characterize, quantify, visualize, and track disease progression over time across the entire patient journey. This approach aims to reduce cognitive burden for clinicians, support acute treatment and transfer decisions, and enable improved longer-term patient management, integrating seamlessly into existing PACS, EHR, and care-team workflows.

Related Companies

Suggest an Edit →